<?xml version="1.0" encoding="UTF-8"?>
<p id="p0030">Influenza A virus (IAV) infection is a major cause of acute respiratory tract diseases and is associated with respiratory syndromes ranging from mild to life-threatening conditions, which constitutes one of the serious threats to the public health worldwide. In 1918, the outbreak of the Spanish flu caused more than 50 million deaths [
 <xref rid="bib1" ref-type="bibr">1</xref>]. In recent decades, continuing transmission of low pathogenic seasonal H1N1 or high pathogenic H5N1 and H7N9 between humans poses a pandemic threat [
 <xref rid="bib2" ref-type="bibr">[2]</xref>, 
 <xref rid="bib3" ref-type="bibr">[3]</xref>, 
 <xref rid="bib4" ref-type="bibr">[4]</xref>]. Vaccination and antiviral drugs such as oseltamivir are efficient approaches for controlling influenza symptoms, but numerous studies reported that they are insufficiency in protecting against an emerging pandemic due to antigenic drift. Therefore, continuing efforts are required to identify novel agents that may effectively fight future influenza pandemics.
</p>
